Description
INCORPORATE THE 2026-2027 APPROVED SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79725D0010
Base award description: NEW AWARD FOR BUPROPION TABLETS WITH MAJOR. PERIOD OF PERFORMANCE IS 3/1/2025-2/28/2026 WITH FOUR ONE-YEAR OPTIONS
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2024-12-31+$0= $0
- Mod P000012025-07-17+$0= $0
- Mod P000022026-01-28+$0= $0
- Mod P000032026-05-12+$0= $0
- Mod P000042026-08-10+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2024-12-31 | +$0 | $0 | NEW AWARD FOR BUPROPION TABLETS WITH MAJOR. PERIOD OF PERFORMANCE IS 3/1/2025-2/28/2026 WITH FOUR ONE-YEAR OPT… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2025-07-17 | +$0 | $0 | INCORPORATE THE 2025-2026 APPROVED SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79725D0010 |
| Mod P00002· EXERCISE AN OPTION | 2026-01-28 | +$0 | $0 | EXERCISE THE FIRST OPTION YEAR FOR BUPROPION HCL TABLETS CONTRACT 36E79725D0017 WITH THE HARVARD DRUG GROUP,… |
| Mod P00003· ENTITY ADDRESS CHANGE | 2026-05-12 | +$0 | $0 | MODIFICATION TO CHANGE THE VENDOR CORPORATE ADDRESS. THE PLACES OF PERFORMANCE REMAIN UNCHANGED |
| Mod P00004· ADD SUBCONTRACTING PLAN | 2026-08-10 | +$0 | $0 | INCORPORATE THE 2026-2027 APPROVED SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79725D0010 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI CBGGKKVNJBK9)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79725D0121 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36E79725D0001 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36E79722D0017 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79721D0048 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
| 36E79721D0038 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
| 36F79719D0033 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2019 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79725D0010_3600 · retrieved 2026-09-26.